title: Phase I study of methylacetylenic putrescine, an inhibitor of polyamine biosynthesis.
abstract: In a phase I clinical trial, nine patients with advanced malignancies not amenable to alternative therapy received alpha-methyl-delta-acetylenic putrescine (MAP), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase (ODC). MAP was given orally in increasing doses to successive groups of three patients as follows: 375 mg, 750 mg and 1500 mg/day, given as three equally divided doses for 4 weeks. Doses of 375 and 750 mg/day were well tolerated, with no detectable toxicity. Of three patients receiving 1500 mg/day, two experienced moderate to severe myelosuppression; one of these also became anuric, requiring the discontinuation of therapy after 9 days. Both effects were reversible after treatment was stopped. No objective responses were observed, with five patients having stable disease and four, progressive disease during the study period. In the seven patients in whom it could be calculated, the plasma elimination half-life t1/2 of MAP measured on the last day of treatment was between 3.9 and 9.2 h in six patients (mean, 5.6 h) and 26.1 h in the seventh. Mean steady-state trough concentrations of MAP were 2.3 mumol after the 375 mg/day dose, 7.1 mumol after 750 mg/day and 16.6 mumol after dosing with 1500 mg/day for 4 weeks, the levels after each treatment schedule being sufficient to inhibit ODC as demonstrated by increases in the urinary excretion of decarboxylated S-adenosylmethionine (dc-SAM). MAP treatment was associated with mean maximal increases in the urinary excretion of dc-SAM of 2.6-, 9.3- and 17.9-fold after 375, 750 and 1500 mg/day for 4 weeks, respectively, but no consistent changes in the urinary excretion of the polyamines, putrescine, spermidine or spermine were observed. Thus, the 24-h urinary excretion of dc-SAM may be used as a conveniently accessible marker of ODC inhibition in cancer patients.
authors.affiliation: Department of Clinical Oncology, University of Edinburgh, Scotland.
authors.forename: M A
authors.initials: MA
authors.lastname: Cornbleet
authors.forename: A
authors.initials: A
authors.lastname: Kingsnorth
authors.forename: G P
authors.initials: GP
authors.lastname: Tell
authors.forename: K D
authors.initials: KD
authors.lastname: Haegele
authors.forename: A M
authors.initials: AM
authors.lastname: Joder-Ohlenbusch
authors.forename: J F
authors.initials: JF
authors.lastname: Smyth
mesh_terms: D000328:Adult; D000368:Aged; D000480:Alkynes; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003959:Diamines; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D011073:Polyamines / Q000037:antagonists & inhibitors*; D011700:Putrescine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000652:urine; D012016:Reference Values; D013095:Spermidine / Q000652:urine; D013096:Spermine / Q000652:urine
chemical_list: D000480:Alkynes; D000970:Antineoplastic Agents; D003959:Diamines; D011073:Polyamines; D013096:Spermine; C039613:6-heptyne-2,5-diamine; D013095:Spermidine; D011700:Putrescine